Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Oncology Right
  3. Cyramza (ramucirumab) injection Right
  4. How is CYRAMZA® (ramucirumab) administered?
Search Cyramza (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Cyramza ® (ramucirumab) injection

10 mg/mL solution

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

How is CYRAMZA® (ramucirumab) administered?

Administer diluted ramucirumab as an intravenous infusion only. Do not administer as an intravenous push or bolus.

US_cFAQ_RAM017_ADMINISTRATION
US_cFAQ_RAM017_ADMINISTRATION
en-US

Calculation and Preparation of Ramucirumab for Administration

Visually inspect vials for particulate matter and discoloration. Discard if particulate matter or discolorations are identified.1

Calculate the dose and the required volume of ramucirumab needed for the calculated dose. Withdraw the required volume of ramucirumab and further dilute with only 0.9% sodium chloride injection in an intravenous (IV) infusion container to a final volume of 250 mL. Do not use dextrose-containing solutions.1

Gently invert the container to ensure adequate mixing. Do not shake the infusion solution. Do not dilute with other solutions or co-infuse with other electrolytes or medications.1

Do not freeze. Store diluted solution for no more than 24 hours at 2°C to 8°C (36°F to 46°F) or 4 hours at room temperature (below 25°C [77°F]).1

Administration of Ramucirumab

Administer ramucirumab as an IV infusion only. Do not administer ramucirumab as an IV push or bolus.1

Administer diluted ramucirumab solution via infusion pump through a separate infusion line. Use of a protein sparing 0.22 micron filter is recommended. Flush the line with sterile 0.9% sodium chloride injection at the end of the infusion.1

If the first 60-minute infusion of ramucirumab is tolerated, then all subsequent infusions may be administered over 30 minutes. This applies to all recommended doses of ramucirumab and all approved indications.1

Discard any unused portion of ramucirumab as the product contains no preservatives.1

Enclosed Prescribing Information

CYRAMZA® (ramucirumab) injection, for intravenous use, Lilly

Reference

1Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.

Date of Last Review: April 25, 2022

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly